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ABSTRACT
Background Germline mutations in the phosphatase
PTEN are associated with diverse human pathologies,
including tumour susceptibility, developmental
abnormalities and autism, but any genotype-phenotype
relationships are poorly understood.
Methods We have studied the functional consequences
of seven PTEN mutations identiﬁed in patients diagnosed
with autism and macrocephaly and ﬁve mutations from
severe tumour bearing sufferers of PTEN hamartoma
tumour syndrome (PHTS).
Results All seven autism-associated PTEN mutants
investigated retained the ability to suppress cellular AKT
signalling, although ﬁve were highly unstable. Observed
effects on AKT also correlated with the ability to
suppress soma size and the length and density of
dendritic spines in primary neurons. Conversely, all ﬁve
PTEN mutations from severe cases of PHTS appeared to
directly and strongly disrupt the ability to inhibit AKT
signalling.
Conclusions Our work implies that alleles causing
incomplete loss of PTEN function are more commonly
linked to autism than to severe PHTS cases.
INTRODUCTION
Phosphatase and tensin homologue deleted on
chromosome ten (PTEN) is a phosphatase that sup-
presses the activity of the class I phosphoinositide
3-kinase/AKTsignalling pathway.
1 It has been heavily
studied due to its status as a tumour suppressor gene
in which loss of function mutations are identiﬁed in
many sporadic tumours and in the germline of
patients with diverse phenotypes. Inherited dominant
PTEN mutations have been identiﬁed in patients
with Cowden syndrome and Bannayan-Riley-
Ruvalcaba syndrome, conditions that are often
grouped together as PTEN hamartoma tumour syn-
drome (PHTS). They have also been identiﬁed in a
fraction of patients with autism spectrum disorder
(ASD) who also display macrocephaly with and
without additional developmental phenotypes char-
acteristic of PHTS.
2–8 Supporting the causality of
PTEN mutations in these phenotypes, a similar
tumour spectrum and autism-like phenotypes have
been identiﬁed in mice either carrying a single null
Pten allele or with tissue-speciﬁc deletion of Pten.
9–11
The major diagnostic criteria for PHTS include
malignancies of the breast, thyroid and endomet-
rium in addition to benign hamartomas, skin lesions
and macrocephaly.
12 However, the symptoms asso-
ciated with PTEN mutations are diverse and in
some cases, germline mutations have been identiﬁed
in adult patients only upon presentation with malig-
nancy
13 14 and in patients with macrocephaly,
autism and/or learning disability without further
symptoms.
51 5A series of clinical and laboratory
based studies have presented evidence that muta-
tional functional diversity and genetic background
may each contribute to the phenotypical diversity
observed in patients carrying PTEN mutations. In
some families, individuals carrying the same PTEN
mutation have been noted to display very different
phenotypes, to the extent of separate diagnoses of
Cowden syndrome and Bannayan-Riley-Ruvalcaba
syndrome.
16 17 Additionally, the spectrum of
tumours arising in heterozygous mice carrying a
null allele of Pten also appears to be strongly
dependent on genetic background.
18 Studies of the
mutation types (missense vs truncation) and posi-
tions (phosphatase vs C2 domain) within PTEN
have argued for
19 and against
22 0genotype-
phenotype relationships. On the other hand, evi-
dence that not all PTEN mutations cause one
phenotypical proﬁle has been provided by studies of
heterozygous mice expressing a stable Pten mutant
protein either lacking all phosphatase activity, Pten
C124S or that selectively lacks lipid phosphatase
activity, Pten G129E. These mice display a more
severe tumour phenotype than mice carrying a Pten
deletion allele
21 22 indicating that inactive Pten can
aggravate phenotypes, particularly tumour severity,
through dominant negative mechanisms. However,
whether this represents a consistent genotype-
phenotype relationship within PTEN mutation car-
riers, in particular relating to the occurrence of
ASD, is unclear.
RESULTS
PTEN missense mutations identiﬁed in patients
with autism are catalytically competent
Recombinant PTEN protein puriﬁed from bacteria
has been used in many previous studies to demon-
strate that phosphatase activity is critical for its
tumour suppressor function. In preliminary experi-
ments studying three PTEN mutants identiﬁed in
patients with autism, we could detect little or no cata-
lytic activity in vitro from protein puriﬁed from bac-
teria, yet transient expression of these mutants in
mammalian cells led to a robust suppression of the
phosphorylation of the PTEN regulated kinase AKT
(see online supplementary ﬁgure S1A, B). This appar-
ent difference between assay formats encouraged us
to analyse a larger group of seven mutant proteins
identiﬁed in patients with autism (ﬁgure 1A) lacking
other manifestations of PHTS.
3–7 Therefore, we used
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missense PTEN mutants (C124S, G129R, H118P ,H 1 2 3 Q ,
E157G, F241S, D252G, N276S and D326N) in PTEN-null
U87MG glioblastoma cells. These include two recognised active
site PTEN mutants that lack catalytic activity: PTEN C124S and
PTEN G129R. We expressed PTEN WT and each mutant using
ﬁve increasing doses of each viral vector (ﬁgure 1C). Investigating
effects on cellular AKT phosphorylation, when expressed at
similar levels, all seven of the autism-related mutants showed
similar (or in some cases possibly greater) effects to PTEN WTon
AKT phosphorylation, whereas a lack of activity was observed
with the inactive mutants PTEN C124S and G129R (ﬁgure 1C, D
and see online supplementary ﬁgure S3A). These data show that
the mutations identiﬁed in patients with autism do not greatly
reduce the ability of the expressed PTEN proteins to inhibit cellu-
lar AKT signalling and imply that these mutants retain catalytic
activity.
To test their phosphatase activity directly, we overexpressed
each protein in U87MG cells and assayed freshly immunopuri-
ﬁed PTEN proteins in vitro against radiolabelled phosphatidyli-
nositol 3,4,5-trisphosphate (PIP3) vesicles. Recovered activities
were weak for many of the PTEN mutants, but this correlated
with a low recovery of immunoprecipitated PTEN, probably due
to poor stability of these mutants during the immunopuriﬁcation
process (see online supplementary ﬁgure S2). In particular,
PTEN H118P , F241S, D252G and N276S were recovered poorly
and gave very weak activity. Activity normalised to reﬂect PTEN
protein content showed robust activity for all mutants, although
weaker than wild type enzyme (see online supplementary ﬁgure
S2). These experiments also indicate that testing the protein
phosphatase activity would be problematic. In addition to this
difﬁculty immunoprecipitating active protein, during these
experiments, it was noted that to express most of the autism-
related PTEN missense mutations at the same level as PTEN WT
protein, a higher titre of lentivirus was consistently required (see
online supplementary ﬁgures S2A and S3A). Therefore, we inves-
tigated the possibility that these mutations affected the stability
of the PTEN protein.
Reduced protein stability of autism-associated
PTEN mutants
To investigate the relationship between the cellular abundance
of PTEN mRNA and protein for the mutants, we expressed
PTEN WT and mutants in U87MG cells and measured PTEN
mRNA levels by real-time qPCR and protein by western blot-
ting. In all cases, the mRNA abundance corresponded to the
titre of lentivirus applied in the experiment. The expression of
PTEN WT and the widely used stable mutants, C124S and
G129R was robust and similar, as was the expression of two of
the autism-associated mutants, H123Q and E157G. However,
we observed that for ﬁve of the autism-associated mutants
(H118P , F241S, D252G, N276S and D326N) the amount of
protein expressed was very low (ﬁgure 1D, E).
To assess more directly the stability of these mutant proteins
relative to PTEN WT, we used the protein synthesis inhibitor
cycloheximide (200 mg/mL). Transduced cells were incubated
with the inhibitor for 0 h, 2 h, 4 h, 6 h and 8 h, followed by
immunodetection using anti-PTEN antibody (ﬁgure 2A, B).
Whereas the protein level of PTEN WT and some mutants
(C124S, G129R, H123Q and E157G) was reduced by ∼20%
after 8 h of inhibition of protein synthesis, the protein level for
the PTEN mutants H118P , F241S, D252G, N276S and D326N
Figure 1 PTEN lipid phosphatase
activity. (A) A diagram representing
PTEN protein structure and the
localisation of the autism-related
mutations analysed. (B) PTEN crystal
structure indicating mutations. The
catalytic Cys-124 is yellow. (C) U87MG
cells were transduced with different
units (low to high) of lentivirus particles
encoding for PTEN WT or PTEN
mutants. Control cells were transduced
with viruses encoding for GFP and
treated with the phosphoinositide
3-kinase (PI3K) inhibitor PI103 (1 mM
for 30 min). PTEN expression and AKT
phosphorylation were investigated by
western blotting of cell lysates. The
presented blotting panels for each
protein are all from one membrane and
are representative of three independent
experiments. (D and E) The level of
PTEN gene expression was measured by
qPCR in U87MG cells transduced with
an equal amount of lentivirus particles
(two units) encoding for PTEN WT or
mutants. (D) Relative PTEN expression
was detected using real-time qPCR.
Data are shown as mean PTEN ΔCt
values relative to GAPDH±SEM. from
three experiments each performed in
duplicate. (E) Parallel PTEN protein
immunoblot. GFP, green ﬂuorescent
protein; GAPDH, glyceraldehyde
3-phosphate dehydrogenase.
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cantly lower than PTEN WT, supporting the hypothesis that
these ﬁve mutants are unstable.
Molecular characterisation in primary neurons of the PTEN
mutations identiﬁed in patients with autism
Macrocephaly is one of the several anatomical and cellular abnor-
malities that have been suggested to be important factors in the
pathogenesis of ASD.
23 Work carried out in mice showed that
PTEN can control neuronal morphology and growth, with hyper-
trophy and dendritic overgrowth and development of macroceph-
aly and additional behavioural phenotypes similar to human
autism observed in mice lacking PTEN in neurons.
10 24–27 We
have therefore used neurons from which endogenous Pten is
deleted to investigate whether the physiological level re-expression
of PTEN WT or autism-associated PTEN mutants is able to
support a wild type phenotype of normal dendritic growth and
neuronal size. Hippocampal neurons prepared from E15.5 ﬂox/
ﬂox Pten mice were transduced simultaneously with lentiviruses
expressing Cre recombinase (RFP-Cre) to delete endogenous Pten
and with viruses encoding PTEN WT or PTEN mutants. The
mutants PTEN H123Q, F241S and D326N were selected to rep-
resent a range of protein stabilities (see ﬁgure 2). The deletion of
the endogenous Pten genes and the re-expression of human PTEN
mutants were veriﬁed by western blot (ﬁgure 3D). Deletion of
Pten led to an increase in Akt phosphorylation which was not
reduced by the expression of PTEN C124S. The mutant F241S
expressed very poorly, however the mutants H123Q and D326N
were expressed and able to downregulate Akt phosphorylation as
was PTEN WT. These results conﬁrmed that when expressed at
physiological levels these mutants are biologically active. We
wanted then to verify the effect that they have on soma size and
the morphology of dendritic spines by immunocytochemistry. In
order to analyse neuronal morphology, 6 days after transduction
and 24 h before being ﬁxed and stained, neuronal cultures were
lipofected with vectors encoding yellow ﬂuorescent protein to
allow the morphological analysis of a transfected neuronal
subpopulation (including identiﬁable transduced and untrans-
duced cells). PTEN WTsigniﬁcantly reduced the soma size (ﬁgure
3B, C) of hippocampal neurons, as well as the density and length
of dendritic spines (ﬁgure 3E–G) to levels similar to control
neurons (from which endogenous Pten had not been deleted),
relative to neurons expressing Cre, with or without additional
inactive PTEN C124S. In agreement with the previous results, we
found that the autism-related mutants H123Q and D326N were
capable of controlling these morphological changes in broad cor-
relation with the amount of protein expressed, showing effect
similar to PTEN WTwhen expressing similar amount of protein.
PTEN F241S expressed very poorly and did not affect neuronal
signalling or morphology in accordance with its very low apparent
stability.
PTEN mutations identiﬁed in severe cases of PHTS
lack activity
Considering the view that patients diagnosed only with ASD
and macrocephaly may reﬂect a group at the milder end of the
spectrum of phenotypes associated with PTEN mutations, we
chose to select a comparator group of mutations associated with
a severe tumour bearing PHTS phenotype. To do this, we con-
ducted an extensive search of data published in journals and
online resources associating speciﬁc PTEN mutations with
phenotype (see online supplementary tables S1–S3). Although
inconsistencies in the categorisation of patients’ severity are
likely to be introduced by diversity in the diagnosis and record-
ing of separate phenotypical characteristics between publica-
tions, our analysis identiﬁed 112 missense mutations that had
sufﬁcient associated phenotypical data and which had been
identiﬁed in a total of 204 patients (see online supplementary
tables S2, S3). This analysis shows that missense mutations
(rather than truncating mutations) were overrepresented among
all PTEN mutation carriers described with ASD compared with
all carriers of PTEN mutations, consistent with the hypothesis
that more of these mutants may retain some activity (ﬁgure S3).
Figure 2 Autism-associated PTEN
mutations reduce protein stability. The
stability of PTEN mutation proteins was
determined using the cycloheximide
inhibitor. (A) U87MG cells expressing
PTEN WT or PTEN point mutants were
treated with 200 mg/mL of the inhibitor
cycloheximide for the indicated times,
followed by immunoblotting analysis
with anti-PTEN and anti-GAPDH
antibodies. The blots shown are
representative of three experiments.
(B) Plot is densitometric quantitation of
the cycloheximide chase assay. Data
are shown as PTEN level normalised to
GAPDH at each time point and
compared with that at the 0 time point.
The quantitation of the cycloheximide
inhibitor assay is derived from three
independent experiments (mean±SEM).
Six independent experiments for PTEN
WT, C124S, H118P and G129R
(including the data shown in ﬁgure
4D, E). ****p<0.0001, ***p<0.001,
**p<0.01, *p<0.05 compared with
PTEN WT (Student’s t test using
GraphPad Prism software).
130 Spinelli L, et al. J Med Genet 2015;52:128–134. doi:10.1136/jmedgenet-2014-102803
Cancer genetics
group.bmj.com  on February 20, 2015 - Published by  http://jmg.bmj.com/ Downloaded from Five PTEN missense mutations associated with the most
severe phenotype (score >6) were selected for characterisation
(PTEN A39P , N48K, L108P , L112P and R130L (ﬁgure 4A)).
These were expressed in U87MG cells together with the already
described stable and inactive PTEN mutants C124S, G129R and
G129E. The latter two have been identiﬁed in Cowden syn-
drome sufferers and in our classiﬁcation were associated with a
mild/moderate phenotype. When transduced into U87MG cells
using lentiviruses, two of these mutant cDNAs (A39P and
N48K) were expressed with similar efﬁciency to WT PTEN but
did not suppress cellular AKT phosphorylation (ﬁgure 4C). The
other three mutants (L108P , L112P and R130L) expressed less
efﬁciency compared with PTEN WT, but when expression was
forced to this level, they also failed to downregulate AKT phos-
phorylation (ﬁgure 4C and see online supplementary ﬁgure
S3B). Analysis of the half-life of PTEN mutant proteins showed
that two of the mutations (L108P and L112P) destabilise the
protein with a decrease in protein levels by ∼60–80% after 8 h
of protein synthesis inhibition, whereas the protein level for the
mutants A39P , N48K and R130L, as well as for PTEN WT,
C124S, G129E and G129R was reduced by ∼20%
(ﬁgure 4D, E). This ﬁnding that when expressed at the same
level as wild type PTEN, all the seven PTEN mutations
associated with ASD, but none of the ﬁve associated with severe
Cowden syndrome analysed was able to regulate AKT is signiﬁ-
cant (two-tailed Fisher’s exact test p=0.0013).
DISCUSSION
Our data show that all seven PTEN mutant proteins that we
investigated due to their identiﬁcation in patients with ASD
retained the capacity to suppress cellular phosphoinositide
3-kinase-AKT signalling when they were expressed to the same
level as wild type PTEN. However, most of these mutant PTEN
proteins are unstable and it would be expected that in vivo this
instability would lead to a very considerable reduction in
protein abundance relative to PTEN WT and a resultant reduc-
tion in biological activity. Functional evaluation of PTEN
mutants in a yeast based system has previously found signiﬁ-
cantly lower activity in a set of PHTS/Cowden-associated PTEN
mutations than in autism-associated mutations,
28 although it
was unclear whether this effect related to direct inactivating
mutations or poor protein stability. It has already been reported
for another mutant associated with ASD, PTEN H93R, that this
mutation caused a signiﬁcant reduction in activity in vitro and
in cells, to approximately 15% of wild type activity in vitro.
29
In agreement with our own data, it seems possible that strong
Figure 3 Characterisation of autism-
related PTEN mutants in primary
neurons. Re-expression at physiological
level of PTEN WT and mutants in PTEN
knockout neurons is able to support
wild type neuronal morphology. (A)
Workﬂow of the experiment. Neurons
were transduced after 7 days with
viruses encoding Cre recombinase
(RFP-Cre) and PTEN WT or mutants as
indicated. Cells were lipofected with
yellow ﬂuorescent protein (YFP) and
then ﬁxed and immunostained 6 days
after transduction for GFP (to detect
YFP), PTEN and for RFP (RFP-Cre) as
showed in the representative images in
(B) (scale bars 10 mm). (C) The soma
size was measured using ImageJ
software and the area measured
(green lines) is represented in mm2
±SEM (n=9 cells for each genotype).
(D) Parallel neuronal cell lysates were
used for western blotting to verify the
efﬁciency of the knockout and the
re-expression of PTEN. (E–G) Effects of
PTEN expression on spine density and
length. (E and F) Quantiﬁcation of the
effects of PTEN genotype on spine
density (n=8 dendrites for each
genotype) and spines length (n=40
spines measured for each mutant) as
mean±SEM. Spines were counted on a
dendrite length of 70 mm.
****p<0.0001, ***p<0.001,
**p<0.01, *p<0.05 compared with
PTEN WT. (Dunnett’s post hoc test
following a one-way ANOVA using
GraphPad Prism software). (G)
Representative images of dendritic
spines (scale bars 10 mm).
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of ASD symptoms in the absence of some of the more severe
phenotypes seen in some patients with Cowden syndrome. In
this regard, we have observed mutations that would lead to loss
of function through instability and through direct incomplete
loss of activity.
In contrast, when a set of PTEN mutations associated with
the most severe cases of Cowden syndrome were tested for their
cellular activity, all of these ﬁve mutant proteins were found to
display no detectable effect on AKT phosphorylation even when
overexpressed. This implies that complete loss of activity may
associate with a more severe PHTS/Cowden phenotype. Of
these ﬁve proteins, three showed stability similar to wild type
PTEN, whereas two were unstable. In the cases of the stable
mutants, this supports a hypothesis that the expression of stable
inactive protein may exacerbate the phenotype caused by PTEN
loss of function, through interference with the functions of the
remaining WT PTEN protein and possibly other proteins.
Strong evidence supporting the potential importance of this
effect comes from the observed phenotypes of Pten knockin
mice, in which the most severe tumour phenotype was observed
in mice expressing stable PTEN mutants lacking lipid phosphat-
ase activity, G129E or C124S, relative to either mice carrying a
Pten deletion or with an unstable PTEN mutation.
21 22
However, other mechanisms may be involved as this would not
seem to explain the occurrence of unstable catalytically inactive
PTEN mutants (L108P and L112P) in severe PHTS. Therefore,
although the mechanisms mediating these effects are unclear,
our work characterises a novel correlation between speciﬁc
human patient groups and the features of the PTEN mutations
they carry.
Our work implies that mutation-speciﬁc factors do contribute
to the severity of PTEN mutation carriers’ symptoms. These
effects may relate to the retention of some biological PTEN
activity in the case of patients displaying macrocephaly and ASD
in the absence of more severe developmental phenotypes, and
to the expression of dominant negative inactive PTEN protein
in some cases combining severe developmental and eventually
tumour phenotypes. Biochemically, potential dominant negative
effects of mutant PTEN proteins have not been extensively
studied, although data supporting the functional importance of
PTEN dimerisation has very recently been published.
21 The ﬁrst
trials are underway of potential targeted therapies, such as inhi-
bitors of the mammalian target of rapamycin (mTOR) kinase
activated downstream of PTEN loss, to treat patients with inher-
ited PTEN mutations and severe phenotypes. Through a deeper
understanding of the signalling mechanisms driving speciﬁc phe-
notypes, it may eventually be possible to tailor treatments to
individual patient groups based upon their early symptoms and
on an understanding of the cellular effects of deﬁned classes of
mutation.
MATERIALS AND METHODS
Cell culture
U87MG glioblastoma cells culture, lentivirus preparation and
titration were as previously described.
30 U87MG cells were
Figure 4 Missense PTEN mutations
associated with severe PTEN
hamartoma tumour syndrome (PHTS)
phenotypes cause complete loss of
function. (A) Studied mutations in PTEN
associated with PHTS. (B) PTEN crystal
structure with catalytic Cys124 in
yellow and indicated mutations.
(C) PTEN null U87MG cells were
transduced with lentiviruses encoding
PTEN WT or mutants. Speciﬁc lentiviral
doses were used for each mutant to
standardise PTEN expression level
(5 units are equal to 50 mL of viral
supernatant). Cell expressing GFP and
cells treated with the phosphoinositide
3-kinase (PI3K) inhibitor PI103 (1 mM,
30 min) were controls. PTEN expression
and AKT and PRAS40 phosphorylation
were investigated by immunoblotting of
total cell lysates. (D and E) U87MG
cells were transduced with PTEN WT or
mutants, treated with 200 mg/mL
cycloheximide, lysed at the indicated
times and then immunoblotted for
PTEN and GAPDH. (D) PTEN protein
levels normalised to GAPDH from three
independent experiments (mean±SEM).
Six independent experiments for PTEN
WT, C124S, H118P and G129R
(including the data shown in ﬁgure 2).
****p<0.0001, ***p<0.001,
**p<0.01, *p<0.05 compared with
PTEN WT (Student’s t test using
GraphPad Prism software). (E) The blots
shown are representative of three
independent experiments.
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with polybrene (16 mg/mL; hexadimethrine bromide, Sigma).
Media were changed 24 h after transduction, and after a further
24 h cells were processed. To delete the Pten gene from cultured
Pten ﬂox-ﬂox murine neurons, a modiﬁed lentiviral vector was
used in which the expression of the RFP-Cre transgene is driven
by a human synapsin-1 promoter.
31 32 RFP-Cre lentiviruses
were produced by triple cotransfection of 6.5 million
HEK293 T cells in 75 cm ﬂasks with 10 mg lentiviral vector,
7.5 mg pHR-CMV 8.9 deltaR packaging vector and 5 mg pCMV
VSV-G envelop vector using X-tremeGENE 9 DNA transfection
reagent (Roche). The 10 mL of viral supernatant was harvested
48 h after transfection, ﬁltered using 0.22 m ﬁlter (Millipore)
and the aliquots were snap frozen in liquid nitrogen for 10 min
before storing them at −80°C.
Primary neuron cultures
Hippocampi were isolated from embryonic day 15.5 Pten ﬂox-
ﬂox mice (E15.5) and digested in trypsin to obtain dissociated
cells as described in Kreis et al.
33 Primary hippocampal cells
were resuspended in neurobasal medium supplemented with
B-27 (serum-free supplement) and cultured on poly-L-ornithine
(15 mg/mL, Sigma) coated coverslips at 37°C in 5% CO2 for
immunocytochemistry and biochemical analysis.
RFP-Cre lentivirus particles were added to the neuronal
culture 7 days after seeding, together with lentivirus particles
encoding WT or mutant forms of PTEN and left for 6 days.
Every 2–3 days half of the medium was replaced by fresh
medium. Neuronal cells used for immunocytochemistry were
transfected with yellow ﬂuorescent protein 24 h before ﬁxation
by using Lipofectamine 2000 as transfection reagent (0.6 mg
DNA/0.8 mL Lipofectamine in Optimem). Of the medium
250 mL was removed, collected in a tube, mixed with fresh
media in a 1:1 ratio and incubated at 37°C. Transfection mix
was added to the cells for 20 min and then removed and
replaced by the incubated media. Cells used for biochemical
analysis were washed in phosphate buffered saline (PBS) and
lysed using RIPA buffer (RIPA lysis and extraction buffer,
Thermo Scientiﬁc, 25 mM Tris-HCL pH 7.6, 150 mM NaCl,
1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecylsul-
phate (SDS), protease inhibitors and phosphatase inhibitors).
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